Length-independent telomere damage drives cardiomyocyte senescence
Rhys Anderson(Newcastle Hospitals - Campus for Ageing and Vitality), João F. Passos(Newcastle University), Peter D. Adams(Discovery Institute), Neil Robertson(University of Glasgow), W. Andrew Owens(Newcastle University), Jodie Birch(Newcastle University), Laura C. Greaves(Queen Mary University of London), James L. Kirkland(Cedars-Sinai Medical Center), Diana Jurk(Mayo Clinic in Florida), Clara Correia‐Melo(Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)), Nathan K. LeBrasseur(WinnMed), Simon Tual‐Chalot(Newcastle University), Tamar Tchkonia(Cedars-Sinai Medical Center), Edward Fielder(Newcastle University), Helen M. Arthur(Newcastle University), Rolando Berlinguer‐Palmini(Newcastle University), James Chapman(George Washington University), Jeanne Mialet‐Perez(Centre National de la Recherche Scientifique), Stella Victorelli(Mayo Clinic in Florida), Damien Maggiorani(Centre Hospitalier Universitaire Sainte-Justine), Hanna Salmonowicz(Mayo Clinic in Florida), Angelo Parini(Inserm), Jordan D. Miller(Queen's University), Victorine Douin‐Echinard(Inserm), Gavin D. Richardson(Newcastle University), Mikołaj Ogrodnik(Austrian Cluster for Tissue Regeneration), Anthony B. Lagnado(Mayo Clinic), Emily Dookun(Newcastle University), Carolyn M Roos(Amsterdam UMC Location University of Amsterdam), Anna Walaszczyk(Newcastle University), Jelena Mann(Newcastle University), Carole J. Proctor(Newcastle Hospitals - Campus for Ageing and Vitality), Marissa Schafer(WinnMed), Kathy L. Kolsky(Mayo Clinic in Florida)
Cited by 6
Related Papers
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
|Aging Cell|2015|2.4k
Cellular senescence mediates fibrotic pulmonary disease
|Nature Communications|2017|1.5k
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
|EBioMedicine|2019|1.3k
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
|EBioMedicine|2019|1.2k
Senescence and the SASP: many therapeutic avenues
|Genes & Development|2020|1.1k